Instil Bio Inc Dossier
Qualitative Analysis
Business overview
Instil Bio, Inc. (Nasdaq: TIL) is a clinical-stage biotechnology company that has undergone a complete strategic realignment. Historically focused on developing autologous tumor-infiltrating lymphocyte (TIL) therapies for cancer, the company's business model experienced a major shift following clinical development halts. In August 2024, Instil Bio in-licensed AXN-2510, a bispecific antibody targeting PD-L1 and VEGF, through its wholly owned subsidiary Axion Bio, Inc. However, in January 2026, Axion Bio discontinued the development of AXN-2510 and terminated its license and collaboration agreement with ImmuneOnco Biopharmaceuticals. Currently, Instil Bio is actively seeking to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical needs, while maintaining its lean operational footprint.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Following the discontinuation of AXN-2510, Instil Bio is actively evaluating potential acquisitions and in-licensing opportunities to access promising novel therapeutic candidates in diseases with significant unmet medical needs.
Expected impact: Re-establish an active therapeutic pipeline and position the company for its next phase of growth.
Maintaining a lean cost structure following extensive restructuring, workforce reductions, and the closure of UK manufacturing and clinical operations.
Expected impact: Extend the cash runway beyond 2027, providing financial stability to pursue strategic transactions.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Formerly the core of Instil Bio's clinical pipeline, covering global rights (ex-Greater China) for AXN-2510 and AXN-27M. The partnership was mutually terminated in January 2026, reverting all rights back to ImmuneOnco.
Terms: The original agreement was valued at up to $2 billion in potential milestones. Upon termination in January 2026, rights reverted to ImmuneOnco with a limited wind-down license for Axion Bio.